Adaptive Biotechnologies ADPT 深 沪
等待开盘 05-13 09:30:00 美东时间
13.63
+0.090
+0.66%
华盛通- 最 高13.72
- 今 开13.42
- 成交量 123.34万股
- 最 低 13.26
- 昨 收 13.54
- 总市值 21.81亿
- 52周最高 20.76
- 市盈率 静 --
- 换手率 0.77%
- 52周最低 8.965
- 委 比 -28.70%
- 总股本 1.60亿
- 历史最高 71.25
- 量 比 0.47
- 振 幅 3.40%
- 历史最低 2.28
- 每 手 1
- 风险率 2.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
今天 11:46
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
BTIG Reiterates Buy on Adaptive Biotechnologies, Maintains $22 Price Target
BTIG analyst Mark Massaro reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and maintains $22 price target.
05-06 19:58
财报速睇 | Adaptive Biotechnologies 2026财年Q1营收0.71亿美元，同比增长35.1%；归母净利润亏损0.20亿美元，同比亏损缩窄32.9%
华盛资讯5月6日讯，Adaptive Biotechnologies公布2026财年Q1业绩，公司Q1营收0.71亿美元，同比增长35.1%，归母净利润亏损0.20亿美元，同比亏损缩窄32.9%。
05-06 08:47
财报速睇 | Adaptive Biotechnologies 2026财年Q1营收0.71亿美元，同比增长35.1%；归母净利润亏损0.20亿美元，同比亏损缩窄32.9%
华盛资讯5月6日讯，Adaptive Biotechnologies公布2026财年Q1业绩，公司Q1营收0.71亿美元，同比增长35.1%，归母净利润亏损0.20亿美元，同比亏损缩窄32.9%。
05-06 05:54
Transcript: Adaptive Biotechnologies Q1 2026 Earnings Conference Call
On Tuesday, Adaptive Biotechnologies (NASDAQ:ADPT) discussed first-quarter fina...
05-06 05:29
Adaptive Biotechnologies shares are trading higher after the company reported better-than-expected Q1 financial results.
Adaptive Biotechnologies shares are trading higher after the company reported b...
05-06 04:36
Adaptive Biotechnologies Q1 EPS $(0.13) Beats $(0.17) Estimate, Sales $70.874M Beat $60.850M Estimate
Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 35 percent increase over losses of $(0.20) per share
05-06 04:09
Earnings Scheduled For May 5, 2026
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution Medicines
U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution Medicines April 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Biogen, Equinix and Revolution Medicines on Tuesday. HIGHLIGHTS * Biogen BIIB.O : Piper Sandler raises
04-14 15:45
